EDMONTON, Alberta — Sinoveda is pleased to announce that Health Canada has approved the NPN (Natural Product Number) for Cordyva™ – Sinoveda’s proprietary cordyceps-based product – confirming that it meets Health Canada’s requirements for safety, effectiveness and quality.
“Receiving the NPN for Cordyva at our recommended dosage was a critical step that allows us to conduct trials for confirmation of its efficacy as a therapy for respiratory illnesses, specifically Long Covid,” said Dr. Yun K. Tam, Chief Science Officer, Sinoveda. “We appreciated Health Canada’s approach and engagement with us on the scientific issues that needed to be considered.”
Cordyva™ is currently licensed for sale in Hong Kong under the trade name AntiCo as a therapy for Long Covid and the resolution of persistent respiratory ailments.
Sinoveda plans to announce the commencement of trials and the recruitment of candidates with Long COVID later in the summer. With the receipt of the NPN for Cordyva, Sinoveda plans on initially releasing the product to market as early as September 2024.
The Natural Product Number NPN 80130819 issued to Sinoveda will be located on every product label distributed.
About Sinoveda: Drug Discovery by Decoding Nature
Sinoveda is an Edmonton-based pharmaceutical research company founded in 2006 using its patented Pharmaceutical Platform Technology (PPT) to understand how natural compounds and formulas work in the body.
Sinoveda has multiple products in their pipeline with research underway on the cancer-fighting potential of specific cannabinoids, hormone replacement therapy alternatives and Long COVID. Sinoveda also partners with third-party pharmaceutical researchers to utilize the growing strength of PPT.
They currently have two products commercially available in North America: Effecti-Cal®, an optimized, patented and clinically tested calcium supplement that PPT proved was more effective and eliminated common side effects as compared to alternatives; and Proflexa, a topical product for the relief of aches and pains.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529531078/en/
